Cardiovascular disease (CVD) is the number one killer in the United States, taking nearly a million lives each year. It is well established that high density lipoprotein (HDL) and its major protein constituent apolipoprotein (apo) A-l play a major role in reducing the risk of CVD. However the function of apolipoprotein A-l I, the second most abundant protein in HDL, has not been determined. Studies on apoA-ll have led to mixed conclusions concerning the pro- or anti- atherogenicity of apoA-ll in HDL. This study will test the hypothesis that apoA-ll interacts with apoA-l in HDL in a site-specific manner to modulate HDL function. Furthermore, the effect is based on the relative amounts of apoA-l: apoA-ll present in a given HDL particle. In the Mentored Phase of this project, I will determine how the incorporation of apoA-ll affects apoA-l structure in discoidal reconstituted HDL particles. Relative changes in the solvent accessibility of specific apoA-l sequences in mixed particles vs apoA-l only HDL will be assessed using the hydrogen deuterium exchange technique combined with mass spectrometry (HDX-MS). I will then extend the studies in the Independent Phase to locate conformational changes in apoA-l caused by apoA-ll in HDL particles from human plasma. This will be accomplished in stages. First, I will reconstitute spherical HDL particles that resemble native HDL by incorporating varying ratios of apoA-l:apoA-ll along with native HDL lipids. I will also generate native hybrid HDL particles by incorporating isolated apoA-ll into native HDL particles containing apoA-l only. The apoA-ll induced modifications of apoA-l solvent exposure will then be correlated to functional properties including activation of various HDL remodeling factors including lecithin:cholesterol acyl transferase (LCAT), hepatic lipase (HL), and endothelial lipase (EL). I anticipate that this work will provide significant new information on the role of apoA-ll in lipoprotein metabolism and may suggest new therapeutic approaches for fighting CVD.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Career Transition Award (K99)
Project #
5K99HL087561-02
Application #
7323266
Study Section
Special Emphasis Panel (ZHL1-CSR-M (F1))
Program Officer
Commarato, Michael
Project Start
2006-12-01
Project End
2008-11-30
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
2
Fiscal Year
2008
Total Cost
$88,103
Indirect Cost
Name
University of Cincinnati
Department
Pathology
Type
Schools of Medicine
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Smith, Loren E; Yang, Jun; Goodman, Leah et al. (2012) High yield expression and purification of recombinant human apolipoprotein A-II in Escherichia coli. J Lipid Res 53:1708-15
Gauthamadasa, Kekulawalage; Vaitinadin, Nataraja Sarma; Dressman, James L et al. (2012) Apolipoprotein A-II-mediated conformational changes of apolipoprotein A-I in discoidal high density lipoproteins. J Biol Chem 287:7615-25
Huang, Rong; Silva, R A Gangani D; Jerome, W Gray et al. (2011) Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 18:416-22